环孢菌素

常用名 环孢菌素 英文名 Cyclosporin A
CAS号 59865-13-3 分子量 1202.611
密度 1.0±0.1 g/cm3 沸点 1293.8±65.0 °C at 760 mmHg
分子式 C62H111N11O12 熔点 148-151°C
MSDS环孢菌素的MSDS|SDS|pdf下载 中文版 美版 闪点 736.3±34.3 °C
符号 GHS07 GHS08
GHS07, GHS08
信号词 Danger

 环孢菌素用途


1.新型免疫抑制剂。为由十一个氨基酸组成的环状多肽物质。它抑制体液和细胞传递的免疫功能,而不抑制骨髓,不减少白细胞数。能阻止对移植组织或器官的排斥作用。临床用于肾移植,肝、肺移植及心脏移植,另外,对自身免疫疾病,以及血吸虫病、疟疾、糖尿病、艾滋病等有一定疗效,还有抗炎症性能。

2.治疗白血病、癌、肾移植、结核病等。

3.免疫抑制剂。由十一个氨基酸组成的环状多肽物质。可抑制淋巴细胞生成干扰素。它对网状内皮系统吞噬细胞无影响。环孢素不同于细胞毒类药物的作用,它仅抑制T细胞介导的细胞免疫而不致显著影响机体的一般防御能力。它抑制体液和细胞传递的免疫功能,而不抑制骨髓,不减少白细胞数。能阻止对移植组织或器官的排斥作用。另外,它对自身免疫疾病以及血吸虫病、疟疾、糖尿病、艾滋病等有一定
疗效,还有抗炎症性能。环孢素在临床上主要用于防止异体器官或骨髓移植时
排异等不利的免疫反应,常和糖皮质激素合用。

更多

 环孢菌素物理化学性质

[ 密度 ]: 1.0±0.1 g/cm3
[ 沸点 ]: 1293.8±65.0 °C at 760 mmHg
[ 熔点 ]: 148-151°C
[ 分子式 ]: C62H111N11O12
[ 分子量 ]: 1202.611
[ 闪点 ]: 736.3±34.3 °C
[ 精确质量 ]: 1201.841309
[ PSA ]: 278.80000
[ LogP ]: 3.35
[ 外观性状 ]: 从-15℃的丙酮得白色针状结晶,熔点148~151℃,[α]D20-244°(C=0.6,氯仿)。溶于甲醇、乙醇、丙酮、乙醚或氯仿,微溶于水及饱和碳氢化合物。急性毒性LD50小鼠,大鼠,兔子(mg/kg):107,25,>10静脉注射;2329,1480,>1000口服。
[ 蒸汽压 ]: 0.0±0.6 mmHg at 25°C
[ 折射率 ]: 1.468
[ 储存条件 ]:

2-8℃

[ 稳定性 ]:

从-15℃的丙酮得白色针状结晶,熔点148~151℃,[α]D20-244°(C=0.6,氯仿)。溶于甲醇、乙醇、丙酮、乙醚或氯仿,微溶于水及饱和碳氢化合物。急性毒性LD50小鼠,大鼠,兔子(mg/kg):107,25,>10静脉注射;2329,1480,>1000口服。

[ 计算化学 ]:

1、 疏水参数计算参考值(XlogP):7.5

2、 氢键供体数量:5

3、 氢键受体数量:12

4、 可旋转化学键数量:15

5、 互变异构体数量:16

6、 拓扑分子极性表面积(TPSA):279

7、 重原子数量:85

8、 表面电荷:0

9、 复杂度: 2330

10、同位素原子数量:0

11、确定原子立构中心数量:12

12、不确定原子立构中心数量:0

13、确定化学键立构中心数量:1

14、不确定化学键立构中心数量:0

15、共价键单元数量:1

[ 更多 ]:

1. 性状:白色针状结晶,从-15℃的丙酮中得到。

2. 密度(g/cm3 ,25 ºC):未确定

3. 相对蒸汽密度(g/mL,空气=1):未确定

4. 熔点(ºC):148-151

5. 沸点(ºC):未确定

6. 沸点(ºC,5.2kPa):未确定

7. 折射率(°):未确定

8. 闪点(℉):未确定

9. 比旋光度(º):未确定

10. 自燃点或引燃温度(ºC):未确定

11. 蒸气压(kPa,25ºC):未确定

12. 饱和蒸气压(kPa,60ºC):未确定

13. 燃烧热(KJ/mol):未确定

14. 临界温度(ºC):未确定

15. 临界压力(KPa):未确定

16. 油水(辛醇/水)分配系数的对数值(25℃):未确定

17. 爆炸上限(%,V/V):未确定

18. 爆炸下限(%,V/V):未确定

19. 溶解性(mg/mL):溶于甲醇、乙醇、丙酮、乙醚或氯仿,微溶于水。

 环孢菌素MSDS

Cyclosporin A Revision number: 5
SAFETY DATA SHEET

Section1. IDENTIFICATION
Product name:Cyclosporin A

Revision number:5

Section2. HAZARDS IDENTIFICATION
GHS classification
PHYSICAL HAZARDSNot classified
HEALTH HAZARDS
Acute toxicity (Oral)Category 4
Category 1A
Carcinogenicity
Reproductive toxicityCategory 1B
Reproductive toxicity (Effects on or via lactation) Additional category for effects on or via lactation
ENVIRONMENTAL HAZARDSNot classified
GHS label elements, including precautionary statements
Pictograms or hazard symbols
Signal wordDanger
Hazard statementsHarmful if swallowed
May cause cancer
May damage fertility or the unborn child
May cause harm to breast-fed children
Precautionary statements:
Obtain special instructions before use.
[Prevention]
Do not handle until all safety precautions have been read and understood.
Do not breathe dust/fume/gas/mist/vapours/spray.
Avoid contact during pregnancy/while nursing.
Do not eat, drink or smoke when using this product.
Wash hands thoroughly after handling.
Use personal protective equipment as required.
[Response]IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell.
Rinse mouth.
IF exposed or concerned: Get medical advice/attention.
[Storage]Store locked up.
[Disposal]Dispose of contents/container through a waste management company authorized by
the local government.

Section3. COMPOSITION/INFORMATION ON INGREDIENTS
Substance
Substance/mixture:
Cyclosporin A

Section3. COMPOSITION/INFORMATION ON INGREDIENTS
Components:Cyclosporin A
Percent:>97.0%(LC)(N)
CAS Number:59865-13-3
Synonyms:Cyclosporin
Chemical Formula:C62H111N11O12

Section4. FIRST AID MEASURES
Inhalation:Remove victim to fresh air and keep at rest in a position comfortable for breathing.
Get medical advice/attention.
Skin contact:Remove/Take off immediately all contaminated clothing. Gently wash with plenty of
soap and water. Get medical advice/attention.
Eye contact:Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do. Get medical advice/attention.
Ingestion:Get medical advice/attention.Rinse mouth.
Protection of first-aiders:A rescuer should wear personal protective equipment, such as rubber gloves and air-
tight goggles.

Section5. FIRE-FIGHTING MEASURES
Suitable extinguishingDry chemical, foam, water spray, carbon dioxide.
media:
Specific hazards arising Take care as it may decompose upon combustion or in high temperatures to
from the chemical:generate poisonous fume.
Precautions for firefighters: Fire-extinguishing work is done from the windward and the suitable fire-extinguishing
method according to the surrounding situation is used. Uninvolved persons should
evacuate to a safe place. In case of fire in the surroundings: Remove movable
containers if safe to do so.
Special protectiveWhen extinguishing fire, be sure to wear personal protective equipment.
equipment for firefighters:

Section6. ACCIDENTAL RELEASE MEASURES
Use extra personal protective equipment (P3 filter respirator for toxic particles). Keep
Personal precautions,
protective equipment and people away from and upwind of spill/leak. Entry to non-involved personnel should
emergency procedures: be controlled around the leakage area by roping off, etc.
Environmental precautions: Prevent product from entering drains.
Methods and materials for Sweep dust to collect it into an airtight container, taking care not to disperse it.
containment and cleaning Adhered or collected material should be promptly disposed of, in accordance with
up: appropriate laws and regulations.

Section7. HANDLING AND STORAGE
Precautions for safe handling
Technical measures:Handling is performed in a well ventilated place. Wear suitable protective equipment.
Prevent dispersion of dust. Wash hands and face thoroughly after handling.
Use a closed system if possible. Use a local exhaust if dust or aerosol will be
generated.
Advice on safe handling: Avoid all contact!
Conditions for safe storage, including any
incompatibilities
Storage conditions:Keep container tightly closed. Store in a refrigerator.
Store locked up.
Store away from incompatible materials such as oxidizing agents.
Heat-sensitive
Comply with laws.
Packaging material:

Section8. EXPOSURE CONTROLS / PERSONAL PROTECTION
Engineering controls:Install a closed system or local exhaust. Also install safety shower and eye bath.
Cyclosporin A

Section8. EXPOSURE CONTROLS / PERSONAL PROTECTION
Personal protective equipment
Respiratory protection: Dust respirator, self-contained breathing apparatus(SCBA), supplied air respirator,
etc. Use respirators approved under appropriate government standards and follow
local and national regulations.
Hand protection:Impervious gloves.
Safety goggles. A face-shield, if the situation requires.
Eye protection:
Skin and body protection: Impervious protective clothing. Protective boots, if the situation requires.

Section9. PHYSICAL AND CHEMICAL PROPERTIES
Physical state (20°C):Solid
Crystal- Powder
Form:
Colour:White - Almost white
No data available
Odour:
pH: No data available
Melting point/freezing point:151°C
Boiling point/range:No data available
Flash point:No data available
Flammability or explosive
limits:
Lower:No data available
Upper:No data available
Relative density:No data available
Solubility(ies):
[Water]No data available
[Other solvents]
Very soluble:Methanol, Ether, Acetone, Ethanol
Soluble:Chloroform
Log Pow:2.92

Section10. STABILITY AND REACTIVITY
Chemical stability:Stable under proper conditions.
Possibility of hazardous No special reactivity has been reported.
reactions:
Incompatible materials: Oxidizing agents
Hazardous decomposition Carbon monoxide, Carbon dioxide, Nitrogen oxides (NOx)
products:

Section11. TOXICOLOGICAL INFORMATION
Acute Toxicity:orl-rat LD50:1480 mg/kg
ipr-rat LD50:147 mg/kg
scu-rat LD50:286 mg/kg
ivn-rat LD50:24 mg/kg
Skin corrosion/irritation: No data available
Serious eyeNo data available
damage/irritation:
Germ cell mutagenicity: sce-hmn-lym 1 mg/L
oms-hmn-lym 50 mg/L
Carcinogenicity:orl-man TDLo:259 mg/kg/2W-C
IARC =Group 1 (Carcinogenic to humans)
NTP =a (Known to be carcinogens)
No data available
Reproductive toxicity:
RTECS Number:GZ4120000

Section12. ECOLOGICAL INFORMATION
Ecotoxicity:
Fish:No data available
Crustacea:No data available
Cyclosporin A

Section12. ECOLOGICAL INFORMATION
Algae:No data available
Persistence / degradability: No data available
BioaccumulativeNo data available
potential(BCF):
Mobility in soil
2.92
Log Pow:
Soil adsorption (Koc):No data available
No data available
Henry's Law
constant(PaM3/mol):

Section13. DISPOSAL CONSIDERATIONS
Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system.
Observe all federal, state and local regulations when disposing of the substance.

Section14. TRANSPORT INFORMATION
Does not correspond to the classification standard of the United Nations
Hazards Class:
UN-No:Not listed

Section15. REGULATORY INFORMATION
Safe management ordinance of dangerous chemical product (State Council announces on January 26, 2002
and revised on February 16,2011): Safe use and production, the storage of a dangerous chemical, transport,
loading and unloading were prescribed.


SECTION 16 - ADDITIONAL INFORMATION
N/A

 环孢菌素毒性和生态

环孢菌素毒理学数据:

小鼠,大鼠,兔子静脉注射LD50(mg/kg):107、25、>10;经口:2329、1480、>1000。

环孢菌素生态学数据:

对水是稍微危害的,若无政府许可,勿将材料排入周围环境。

CHEMICAL IDENTIFICATION

RTECS NUMBER :
GZ4120000
CHEMICAL NAME :
Cyclosporin A
CAS REGISTRY NUMBER :
59865-13-3
LAST UPDATED :
199801
DATA ITEMS CITED :
35
MOLECULAR FORMULA :
C62-H111-N11-O12
MOLECULAR WEIGHT :
1202.84

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
1911 mg/kg/91W-I
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Behavioral - coma Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
62500 ug/kg/5D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - other changes Nutritional and Gross Metabolic - body temperature increase
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
20 mg/kg/2D-I
TOXIC EFFECTS :
Behavioral - headache Vascular - acute arterial occlusion Lungs, Thorax, or Respiration - cyanosis
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human
DOSE/DURATION :
12 mg/kg
TOXIC EFFECTS :
Vascular - BP elevation not characterized in autonomic section Endocrine - antidiuresis
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
30 mg/kg/4D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1480 mg/kg
TOXIC EFFECTS :
Behavioral - muscle contraction or spasticity Gastrointestinal - hypermotility, diarrhea Skin and Appendages - hair
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
147 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
286 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
24 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
2329 mg/kg
TOXIC EFFECTS :
Behavioral - muscle contraction or spasticity Gastrointestinal - hypermotility, diarrhea Skin and Appendages - hair
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
96 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
>1 gm/kg
TOXIC EFFECTS :
Behavioral - muscle contraction or spasticity Gastrointestinal - hypermotility, diarrhea Skin and Appendages - hair
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
10 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
140 mg/kg/14D-I
TOXIC EFFECTS :
Endocrine - changes in spleen weight Blood - changes in spleen
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
350 mg/kg/7D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - other changes in urine composition Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - multiple enzyme effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
800 mg/kg/10D-I
TOXIC EFFECTS :
Behavioral - food intake (animal) Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
420 mg/kg/28D-I
TOXIC EFFECTS :
Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Musculoskeletal - other changes
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
700 mg/kg/28D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Kidney, Ureter, Bladder - other changes in urine composition
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
210 mg/kg/14D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - renal function tests depressed Kidney, Ureter, Bladder - other changes in urine composition Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - other transferases
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1200 mg/kg/40D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - other changes in urine composition Biochemical - Metabolism (Intermediary) - amino acids (including renal excretion) Biochemical - Metabolism (Intermediary) - Plasma proteins not involving coagulation
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
140 mg/kg/7D-I
TOXIC EFFECTS :
Vascular - BP elevation not characterized in autonomic section Vascular - regional or general arteriolar or venous dilation
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
60 mg/kg/3D-I
TOXIC EFFECTS :
Vascular - BP elevation not characterized in autonomic section Vascular - structural changes in vessels Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
259 mg/kg/2W-C
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Blood - lymphoma, including Hodgkin's disease
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
166 mg/kg
SEX/DURATION :
male 45 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - other effects on male Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
420 mg/kg
SEX/DURATION :
male 14 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
560 mg/kg
SEX/DURATION :
male 14 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - other effects on male
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
90 mg/kg
SEX/DURATION :
female 6-8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
50 mg/kg
SEX/DURATION :
female 12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
210 mg/kg
SEX/DURATION :
female 14 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Fertility - other measures of fertility

MUTATION DATA

TYPE OF TEST :
Sister chromatid exchange
TEST SYSTEM :
Human Lymphocyte
DOSE/DURATION :
1 mg/L
REFERENCE :
IGAYAY Igaku No Ayumi. Progress in Medicine. (Ishiyaku Shuppan K.K., 1-7-10, Honkomagom, Bunkyo-ku, Tokyo, Japan) V.1- 1946- Volume(issue)/page/year: 134,403,1985 *** REVIEWS *** IARC Cancer Review:Human Sufficient Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,77,1990 IARC Cancer Review:Animal Limited Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,77,1990 IARC Cancer Review:Group 1 IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,77,1990

 环孢菌素安全信息

[ 符号 ]: GHS07 GHS08
GHS07, GHS08
[ 信号词 ]: Danger
[ 危害声明 ]: H302-H350-H360
[ 警示性声明 ]: P201-P301 + P312 + P330-P308 + P313
[ 个人防护装备 ]: Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
[ 危害码 (欧洲) ]: T:Toxic
[ 风险声明 (欧洲) ]: R45;R60;R22
[ 安全声明 (欧洲) ]: 53-45-36/37-24/25-22
[ 危险品运输编码 ]: NONH for all modes of transport
[ WGK德国 ]: 3
[ RTECS号 ]: GZ4120000
[ 海关编码 ]: 2941909000

 环孢菌素上下游产品

环孢菌素上游产品  0

环孢菌素下游产品  2

 环孢菌素制备

1.以多孢木霉菌(Tolypocladium inflatum Cams)为生产菌株。75L罐内装50L种子培养基,接种5×109个孢子,Ph=5.4—4.3,培养72h,得到一级种子液。750L发酵罐内装500L发酵培养基,种入上述一级种子液,培养6天,得二级种子液。4500L发酵罐内装3000L发酵培养基,发酵12天,得到环孢素发酵毒。往发酵液中加人等体积的乙酸乙酯提取,分出有机层,减压蒸发,得粗品。融化处理,可得环孢素和环孢菌素C组分,其中环孢素的产量约为150~200mg/L环孢菌素C约为50~100mg/L。

2.以多孢木霉菌为生产菌株。先制备环孢素发酵液。向发酵液中加入乙酸乙酯提取,分出有机层,减压蒸发,得粗品。经纯化处理可得。

 环孢菌素海关

[ 海关编码 ]: 2941909000

 环孢菌素文献494

更多文献
Proteomic analysis in serum of rat hind-limb allograft tolerance induced by immunosuppressive therapy with adipose-derived stem cells.

Plast. Reconstr. Surg. 134(6) , 1213-23, (2014)

Adipose-derived stem cells combined with transient immunosuppression prolonged vascularized composite tissue allotransplant survival and induced immune tolerance in a rodent hind-limb model. The autho...

Differentiation between human ClC-2 and CFTR Cl- channels with pharmacological agents.

Am. J. Physiol. Cell Physiol. 307(5) , C479-92, (2014)

It has been difficult to separate/identify the roles of ClC-2 and CFTR in Cl(-) transport studies. Using pharmacological agents, we aimed to differentiate functionally between ClC-2 and CFTR Cl(-) cha...

The Ca²⁺-calmodulin-Ca²⁺/calmodulin-dependent protein kinase II signaling pathway is involved in oxidative stress-induced mitochondrial permeability transition and apoptosis in isolated rat hepatocytes.

Arch. Toxicol. 88(9) , 1695-709, (2014)

Oxidative stress (OS) is a common event in most hepatopathies, leading to mitochondrial permeability transition pore (MPTP) formation and further exacerbation of both OS from mitochondrial origin and ...